Drug Trial Radar · NCT01722331
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
Last checked: Nov 20, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
772
Actual
Start
Dec 6, 2012
Primary completion
Oct 28, 2015
Study completion Nov 10, 2021
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
Tildrakizumab 200 mgDrug
Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
Tildrakizumab 100 mgDrug
Tildrakizumab 100 mg/mL PFS
Matching PlaceboDrug
Matching placebo to tildrakizumab PFS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study)Time frame: Week 12 (or end of trial if prior to Week 12)
- Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study)Time frame: Baseline and Week 12 (or end of trial if prior to Week 12)
- Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study)Time frame: Up to 12 weeks
- Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study)Time frame: Up to 12 weeks
- Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study)Time frame: Up to 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.